AbbVie reports SVR24 data for all-oral regimen

AbbVie Inc. (NYSE:ABBV) reported additional data from the Phase IIb Aviator (Study M11-652) trial of an interferon-free regimen that includes three of Abbott's antivirals to treat HCV genotype 1 infection in non-cirrhotic patients. The regimen -- ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks -- produced a sustained virologic response (SVR) 24 weeks after the end of treatment in 96% of treatment-naive patients (n=79) and 93% of null responders (n=45). There was one case of viral relapse in treatment-naïve patients who received ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks, and no cases of viral relapse in null responders receiving the same treatment regimen. Data are slated to be presented on Thursday at the European Association for the Study of the Liver meeting in Amsterdam.

Detailed SVR12 data from the trial were reported last year (see BioCentury, Oct. 22, 2012). ...